logo-loader
RNS
Imaging Biometrics Ltd

Imaging Biometrics - AMENDEMENT TO NOTICE OF ANNUAL GENERAL MEETING

RNS Number : 0578E
Imaging Biometrics Limited
13 May 2026
 

 

Imaging Biometrics Limited

("IBAI" or the "Company")

AMENDEMENT TO NOTICE OF ANNUAL GENERAL MEETING

 

The Company notes an error to RNS 12 May 2026 (RNS Number: 0280E), that incorrectly stated that the ordinary shares of £0.01 will be sub-divided into one ordinary share of £0.0005. The ordinary shares of £0.01 will in fact be sub-divided into one ordinary share of £0.005.

The corrected Notice of AGM will shortly be available at  https://imagingbiometrics.com/. All other resolutions have not been amended.

The corrected announcement reads:

Imaging Biometrics Limited, the Main Market listed healthcare technology group, is pleased to announce that its Annual General Meeting ("AGM") will be held at IFC5, St Helier, Jersey, JE1 1ST on 3 June 2026 at 10:00 am.  

 

The Notice of AGM includes, inter alia, details of a proposed share sub-division whereby each current ordinary share of £0.01 will be sub-divided into one ordinary share of £0.005. The number of ordinary shares in issue will not change and will remain at 246,709,789 ordinary shares of £0.005, assuming that the sub-division resolution is passed at the AGM.

 

A form of proxy will accompany the Notice of AGM and the Noice of AGM will shortly be available at https://imagingbiometrics.com/

 

The Directors of the Company accept responsibility for the contents of this announcement.

 For further information, please contact:

 

Imaging Biometrics Limited

Trevor Brown / Brett Skelly / Michael Schmainda / John Richardson

Tel: 020 7469 0930

AlbR Capital Limited (Corporate Broker)

Lucy Williams / Duncan Vasey

Tel: 020 7220 9797

 

 

Notes to Editors

About Imaging Biometrics Limited

Imaging Biometrics Limited is an LSE-listed healthcare technology group focused on quantitative neuroimaging software and organ-on-a-chip technology. Its principal subsidiary, Imaging Biometrics LLC, is a world leader in advanced MRI analysis software used in the assessment of brain tumours, with products distributed globally including through a commercial agreement with GE HealthCare. Kirkstall Limited, acquired by IBAI in October 2025, develops the Quasi Vivo® organ-on-a-chip platform for use in pharmaceutical research, toxicology testing and disease modelling.

About Kirkstall Limited

Kirkstall Limited is a biotechnology company specialising in microfluidic organ-on-a-chip systems. Its Quasi Vivo® platform enables cells to be maintained under physiological flow conditions that closely mimic the human body, providing pharmaceutical and academic researchers with more predictive and human-relevant in vitro models. Kirkstall has an established international distributor network spanning the United States, China and South Korea.

About Nottingham Trent University

NTU owns two Queen's Anniversary Prizes for outstanding achievements in research (2015, 2021). The Research Excellence Framework (2021) classed 83% of NTU's research activity as either world-leading or internationally excellent. Professor Gareth Cave and his team in the School of Science and Technology work at the interface of pharmaceutical science and biomedical engineering.

About the NC3Rs/BBSRC Business Interaction Voucher Scheme

The Business Interaction Voucher scheme is a joint funding initiative from the NC3Rs and BBSRC designed to support collaboration between academic researchers in the NC3Rs network and commercial partners. The scheme aims to accelerate the development and adoption of human-relevant, animal-free research technologies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFLFETEDIFLIR
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read